{"id":1019029,"date":"2026-11-09T17:43:00","date_gmt":"2026-11-09T22:43:00","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-completes-rolling-bla-submission-seeking-accelerated-approval-of-nomlabofusp-for-friedreichs-ataxia\/"},"modified":"2026-11-09T17:43:00","modified_gmt":"2026-11-09T22:43:00","slug":"larimar-therapeutics-completes-rolling-bla-submission-seeking-accelerated-approval-of-nomlabofusp-for-friedreichs-ataxia","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-completes-rolling-bla-submission-seeking-accelerated-approval-of-nomlabofusp-for-friedreichs-ataxia\/","title":{"rendered":"Larimar Therapeutics Completes Rolling BLA Submission Seeking Accelerated Approval of Nomlabofusp for Friedreich\u2019s Ataxia"},"content":{"rendered":"<div class=\"mw_release\">\n<ul type=\"disc\">\n<li>\n          <em>Completed BLA submission marks a major milestone in advancing nomlabofusp as the first potential disease-modifying therapy to address the underlying cause of FA<\/em><\/p>\n<\/li>\n<li>\n          <em>Submission follows FDA alignment on key elements of the BLA package for submission, including willingness to consider skin frataxin as a potential novel surrogate endpoint<\/em><\/p>\n<\/li>\n<li>\n          <em>Previously reported open label data showed sustained increases in skin frataxin with directional clinical improvements observed in multiple outcomes relative to a natural history reference population<\/em><\/p>\n<\/li>\n<li>\n          <em>Patients currently enrolling in FORWARD-FA, the global confirmatory Phase 3 study for nomlabofusp<\/em>\n        <\/li>\n<\/ul>\n<p>BALA CYNWYD, Pa., Nov.  09, 2026  (GLOBE NEWSWIRE) &#8212; Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced completion of its rolling Biologics License Application (BLA) submission to the U.S. Food and Drug Administration (FDA) seeking accelerated approval of nomlabofusp for the treatment of patients with Friedreich\u2019s ataxia (FA). Nomlabofusp is an investigational protein replacement therapy designed to address the underlying cause of FA, frataxin deficiency, by delivering human frataxin to mitochondria.<\/p>\n<p align=\"justify\">Completion of the submission follows previously disclosed FDA feedback on key elements of the BLA and represents a significant milestone for Larimar. Larimar is currently enrolling patients in FORWARD-FA, its global confirmatory Phase 3 study, a double-blind, placebo-controlled study that will evaluate daily subcutaneous use of nomlabofusp over 18 months in ambulatory participants ages 2 to 40 who are new to the drug. Approximately two thirds of the participants will be under the age of 21.<\/p>\n<p align=\"justify\">\u201cCompleting our BLA submission is a major milestone for Larimar and the FA community, bringing years of development work together in an application seeking accelerated approval of nomlabofusp,\u201d said Carole Ben-Maimon, MD, Chief Executive Officer of Larimar. \u201cOur confidence in the program is grounded in the sustained increases in skin frataxin and consistent directional improvements observed in multiple clinical outcomes in patients. It is important to note that patients with FA are expected to experience continued neurologic decline, not improvement. After treatment with nomlabofusp, we have not observed worsening in most participants but rather signs of improvement. Our previously disclosed discussions with FDA have helped inform the content of the submission. As we support the potential FDA review and advance FORWARD-FA, our confirmatory Phase 3 study, our team is preparing for a potential U.S. launch with the goal of making nomlabofusp available to patients as quickly as possible following approval, if granted. In parallel, we continue to evaluate options to optimize our global commercialization strategy.\u201d<\/p>\n<p align=\"justify\">The BLA seeks accelerated approval based on increases in skin frataxin (FXN) concentrations as a potential novel surrogate endpoint and is supported by data from the ongoing long-term open label (OL) study. <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=oG7JuNv9tqpnzkZ4yvSyAFA0Hh_mO_Zf4Xjt3x-sKpLYgwobHb_jgYtKR7zfXa0hYCkzhi8fY3ftLxwAMR6kLAK5NDsagftJ0l4WOpmkm1TLACCZwbrD5IuZsKBGB5fH_44rzED9QeTalDpLMKLTe_6W2wuOOFPf6J4B18K7ZWiiar9uIiDfnUX21kGD_T9MZwDOrsk_EY4KaXR6_tnKsMBuqeZ0wtHle52HQFEFBauyi2TOImqK6V2tMQzvSmeR\" rel=\"nofollow\" target=\"_blank\">Previously reported findings<\/a> showed sustained increases in skin FXN, with all evaluable participants at one year achieving skin FXN levels within the range expected in asymptomatic heterozygous carriers. Directional improvements were observed at one year across multiple clinical outcomes relative to worsening in a natural history reference population. Directional improvement of exploratory pharmacodynamic markers (plasma lipids and peripheral tissue gene transcription) compared to placebo treated patients were also observed. Nomlabofusp has the potential to be the first disease-modifying therapy for patients with FA.<\/p>\n<p align=\"justify\">\u201cLarimar\u2019s completion of its BLA submission for nomlabofusp marks an important and exciting milestone for the Friedreich\u2019s ataxia community. As the first potential frataxin replacement therapy, nomlabofusp is designed to address the underlying cause of FA. The fact that the submission includes data from adolescents ages 12 to 17 is especially meaningful, as there are currently no approved therapies for children under 16 years of age. FA is a complex and variable disease, and patients and families need multiple treatment options that can address their individual needs across different ages and stages of disease,\u201d said Jen Farmer, M.S., Chief Executive Officer, Friedreich\u2019s Ataxia Research Alliance (FARA).<\/p>\n<p align=\"justify\">\n        <strong>Submission Highlights:<\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li>Data Package Supporting Submission and Review: FDA reviewed OL study data submitted in a briefing package and confirmed in minutes from the multidisciplinary Type B pre-BLA meeting that the existing data package appears capable of supporting submission and review of a BLA seeking accelerated approval of nomlabofusp as a treatment for patients with FA. Approval will be a matter of review.<\/li>\n<li>FXN as a Potential Surrogate Endpoint: In those previously disclosed interactions, FDA reaffirmed its willingness to consider FXN as a novel surrogate endpoint and indicated that Larimar\u2019s exposure-response analysis linking nomlabofusp exposure to clinical outcomes is the type of analysis that could support the BLA submission.<\/li>\n<li style=\"text-align:justify\">Additional Biological Evidence: FDA previously noted that prospectively collected exploratory gene expression and lipid pharmacodynamic markers data may help further characterize the biological activity of nomlabofusp beyond tissue FXN concentrations. <\/li>\n<\/ul>\n<p align=\"justify\">\n        <strong>Potential Upcoming Milestones<\/strong><br \/>\n        \n      <\/p>\n<ul type=\"disc\">\n<li>\n          <strong>BLA Submission Acceptance:<\/strong> Early 2027<\/p>\n<\/li>\n<li>\n          <strong>Open Label Study Safety Update:<\/strong> Q1 2027<\/p>\n<\/li>\n<li>\n          <strong>U.S. Approval:<\/strong> Mid-2027<\/p>\n<\/li>\n<li>\n          <strong>Obtaining &amp; Monetizing the Rare Pediatric Disease Priority Review Voucher: <\/strong>Mid-2027, if approved<\/p>\n<\/li>\n<li>\n          <strong>U.S. Launch: <\/strong>Targeting Q3 2027 launch, if approved.<\/li>\n<\/ul>\n<p>Nomlabofusp has received FDA Breakthrough Therapy Designation for the treatment of FA in adults and children as well as Fast Track, Rare Pediatric Disease, and Orphan Drug designations. Nomlabofusp was also selected for FDA\u2019s Support for Clinical Trials Advancing Rare Disease Therapeutics (START) pilot program, which has enabled more frequent interactions with FDA to support our development and regulatory strategy.<\/p>\n<p align=\"justify\">\n        <strong>About FORWARD-FA<\/strong><br \/>\n        <br \/>FORWARD-FA, Larimar\u2019s global confirmatory Phase 3 study, is designed to assess safety and clinical outcomes and to verify the clinical benefit of nomlabofusp as part of the Company\u2019s accelerated approval strategy. The double-blind, placebo-controlled study will evaluate daily subcutaneous use of nomlabofusp over 18 months in ambulatory participants ages 2 to 40 who are new to the drug. Approximately two thirds of the participants will be under the age of 21. The focus on younger participants reflects the tendency for more rapid disease progression in this population and underscores the need for evaluating potential treatments for early intervention.<\/p>\n<p align=\"justify\">\n        <strong>About Larimar Therapeutics<\/strong><br \/>\n        <br \/>Larimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar\u2019s lead compound, nomlabofusp, is being developed as a potential treatment for Friedreich&#8217;s ataxia. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. For more information, please visit: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=VUJE5O8rEysclbXUdl7hqfF90SFuKrfhCZ048iwfCvMJ_cYF3MvnhxOy4j-wCpmtQDvUkYIenRSm0a0e2RkfVSM9_P4nhNVd7LChr8cjZ-w=\" rel=\"nofollow\" target=\"_blank\">https:\/\/larimartx.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements <\/strong>\n      <\/p>\n<p>This press release contains forward-looking statements that are based on Larimar\u2019s management\u2019s beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including but not limited to statements regarding Larimar\u2019s ability to develop and commercialize nomlabofusp and any other planned product candidates; the potential of nomlabofusp to address the underlying cause of FA and provide clinical benefit; the interpretation of clinical, biomarker and safety data and their ability to support the BLA; expectations regarding the FDA\u2019s acceptance for filing, review and potential approval of the BLA, including consideration of skin FXN as a potential novel surrogate endpoint; Larimar\u2019s planned research and development efforts, including the design, timing and conduct of FORWARD-FA; interactions with FDA; expectations regarding the potential for, accelerated approval or accelerated access and the impact of such accelerated access on the FDA\u2019s review timeline Larimar\u2019s preparations for and timing of a potential launch, if approved; the potential award and future sale of a Rare Pediatric Priority Review Voucher; and Larimar\u2019s overall development plans, business strategies, ability to raise capital, use of capital, results of operations and financial position, and plans and objectives for future operations.<\/p>\n<p>In some cases, you can identify forward-looking statements by the words \u201cmay,\u201d \u201cwill,\u201d \u201ccould,\u201d \u201cwould,\u201d \u201cshould,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cpotential,\u201d \u201ccontinue,\u201d \u201congoing\u201d or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors include, among others, the success, cost and timing of Larimar\u2019s product development activities, nonclinical studies and clinical trials, including nomlabofusp clinical milestones and continued interactions with the FDA; that preliminary clinical trial results may differ from final clinical trial results, that earlier non-clinical and clinical data and testing of nomlabofusp may not be predictive of the results or success of later non-clinical or clinical trials, and assessments; delays in patient recruitment, including as a result of changes in clinical protocols and adverse events; that the FDA may not ultimately agree with Larimar\u2019s nomlabofusp development strategy or determine that skin FXN is not an acceptable surrogate endpoint for accelerated approval; that completion of the BLA submission does not assure acceptance for filing or accelerated approval and that FDA may require additional information or studies; Larimar\u2019s ability to realize the benefits of Breakthrough Therapy Designation; the potential impact of public health crises on Larimar\u2019s future clinical trials, manufacturing, regulatory, nonclinical study timelines and operations, and general economic conditions; Larimar\u2019s ability and the ability of third-party manufacturers Larimar engages, to optimize and scale nomlabofusp\u2019s manufacturing process; Larimar\u2019s ability to obtain regulatory approvals for nomlabofusp and future product candidates; Larimar\u2019s ability to successfully develop sales and marketing capabilities, whether alone or with potential future collaborators, and to successfully commercialize any approved product candidates; Larimar\u2019s ability to raise the necessary capital to conduct its product development activities; and other risks described in the filings made by\u00a0Larimar\u00a0with the\u00a0Securities and Exchange Commission\u00a0(SEC), including but not limited to Larimar\u2019s periodic reports, including the annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, filed with or furnished to the\u00a0SEC\u00a0and available at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=R9Z7HQALFgi7ONTd3mdkHNS1881BtuzzzVxDob-zPO2T3w0jiOMqRNiXgzVGZkZIaQgpFy4RAdv1xLVL7Q12gfA2D7ikkoa3VzkbFaxcp3VxeLm8mimS7xeBTdPd5-wk_c_sNU5qaVfGuFTb51zp3azUKfShXBxlfKLbksvFWhgYeWXo3RN5v7rGuOmJ25Q6XL4fmuaqrC0Oq30pCd7fHE3vxWxK_GM09htUdymai2k=\" rel=\"nofollow\" target=\"_blank\">www.sec.gov<\/a>. These forward-looking statements are based on a combination of facts and factors currently known by\u00a0Larimar\u00a0and its projections of the future, about which it cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent Larimar\u2019s management\u2019s views only as of the date hereof.\u00a0Larimar\u00a0undertakes no obligation to update any forward-looking statements for any reason, except as required by law.<\/p>\n<table style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: justify;vertical-align: middle;vertical-align: top\">\n            <strong>Investor Contact:<\/strong><br \/>\n            <br \/>Joyce Allaire\u00a0\u00a0\u00a0\u00a0\u00a0<br \/>LifeSci Advisors\u00a0<br \/><a href=\"mailto:jallaire@lifesciadvisors.com\" rel=\"nofollow\" target=\"_blank\">jallaire@lifesciadvisors.com<\/a>\u00a0\u00a0 \u00a0\u00a0<br \/>(212) 915-2569<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: justify;vertical-align: middle;vertical-align: top\">\n            <strong>Company Contact:<\/strong><br \/>\n            <br \/>Michael Celano\u00a0<br \/>Chief Financial Officer<br \/><a href=\"mailto:mcelano@larimartx.com\" rel=\"nofollow\" target=\"_blank\">mcelano@larimartx.com<\/a><br \/>(484) 414-2715<\/td>\n<\/tr>\n<\/table>\n<p>\n        \n      <\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3Mjg3OCM3OTUyODg3IzUwMDA3Nzg4OQ==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MmZhZjFlYzgtZmI1ZC00YmY3LTk1ZTgtM2VjODU1ZTc5MWM3LTUwMDA3Nzg4OS0yMDI2LTExLTA5LWVu\/tiny\/Larimar-Therapeutics.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Completed BLA submission marks a major milestone in advancing nomlabofusp as the first potential disease-modifying therapy to address the underlying cause of FA Submission follows FDA alignment on key elements of the BLA package for submission, including willingness to consider skin frataxin as a potential novel surrogate endpoint Previously reported open label data showed sustained increases in skin frataxin with directional clinical improvements observed in multiple outcomes relative to a natural history reference population Patients currently enrolling in FORWARD-FA, the global confirmatory Phase 3 study for nomlabofusp BALA CYNWYD, Pa., Nov. 09, 2026 (GLOBE NEWSWIRE) &#8212; Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced completion of its rolling &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-completes-rolling-bla-submission-seeking-accelerated-approval-of-nomlabofusp-for-friedreichs-ataxia\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Larimar Therapeutics Completes Rolling BLA Submission Seeking Accelerated Approval of Nomlabofusp for Friedreich\u2019s Ataxia&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1019029","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Larimar Therapeutics Completes Rolling BLA Submission Seeking Accelerated Approval of Nomlabofusp for Friedreich\u2019s Ataxia - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-completes-rolling-bla-submission-seeking-accelerated-approval-of-nomlabofusp-for-friedreichs-ataxia\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Larimar Therapeutics Completes Rolling BLA Submission Seeking Accelerated Approval of Nomlabofusp for Friedreich\u2019s Ataxia - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Completed BLA submission marks a major milestone in advancing nomlabofusp as the first potential disease-modifying therapy to address the underlying cause of FA Submission follows FDA alignment on key elements of the BLA package for submission, including willingness to consider skin frataxin as a potential novel surrogate endpoint Previously reported open label data showed sustained increases in skin frataxin with directional clinical improvements observed in multiple outcomes relative to a natural history reference population Patients currently enrolling in FORWARD-FA, the global confirmatory Phase 3 study for nomlabofusp BALA CYNWYD, Pa., Nov. 09, 2026 (GLOBE NEWSWIRE) &#8212; Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced completion of its rolling &hellip; Continue reading &quot;Larimar Therapeutics Completes Rolling BLA Submission Seeking Accelerated Approval of Nomlabofusp for Friedreich\u2019s Ataxia&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-completes-rolling-bla-submission-seeking-accelerated-approval-of-nomlabofusp-for-friedreichs-ataxia\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-09T22:43:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3Mjg3OCM3OTUyODg3IzUwMDA3Nzg4OQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"9 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/larimar-therapeutics-completes-rolling-bla-submission-seeking-accelerated-approval-of-nomlabofusp-for-friedreichs-ataxia\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/larimar-therapeutics-completes-rolling-bla-submission-seeking-accelerated-approval-of-nomlabofusp-for-friedreichs-ataxia\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Larimar Therapeutics Completes Rolling BLA Submission Seeking Accelerated Approval of Nomlabofusp for Friedreich\u2019s Ataxia\",\"datePublished\":\"2026-11-09T22:43:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/larimar-therapeutics-completes-rolling-bla-submission-seeking-accelerated-approval-of-nomlabofusp-for-friedreichs-ataxia\\\/\"},\"wordCount\":1737,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/larimar-therapeutics-completes-rolling-bla-submission-seeking-accelerated-approval-of-nomlabofusp-for-friedreichs-ataxia\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3Mjg3OCM3OTUyODg3IzUwMDA3Nzg4OQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/larimar-therapeutics-completes-rolling-bla-submission-seeking-accelerated-approval-of-nomlabofusp-for-friedreichs-ataxia\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/larimar-therapeutics-completes-rolling-bla-submission-seeking-accelerated-approval-of-nomlabofusp-for-friedreichs-ataxia\\\/\",\"name\":\"Larimar Therapeutics Completes Rolling BLA Submission Seeking Accelerated Approval of Nomlabofusp for Friedreich\u2019s Ataxia - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/larimar-therapeutics-completes-rolling-bla-submission-seeking-accelerated-approval-of-nomlabofusp-for-friedreichs-ataxia\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/larimar-therapeutics-completes-rolling-bla-submission-seeking-accelerated-approval-of-nomlabofusp-for-friedreichs-ataxia\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3Mjg3OCM3OTUyODg3IzUwMDA3Nzg4OQ==\",\"datePublished\":\"2026-11-09T22:43:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/larimar-therapeutics-completes-rolling-bla-submission-seeking-accelerated-approval-of-nomlabofusp-for-friedreichs-ataxia\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/larimar-therapeutics-completes-rolling-bla-submission-seeking-accelerated-approval-of-nomlabofusp-for-friedreichs-ataxia\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/larimar-therapeutics-completes-rolling-bla-submission-seeking-accelerated-approval-of-nomlabofusp-for-friedreichs-ataxia\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3Mjg3OCM3OTUyODg3IzUwMDA3Nzg4OQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3Mjg3OCM3OTUyODg3IzUwMDA3Nzg4OQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/larimar-therapeutics-completes-rolling-bla-submission-seeking-accelerated-approval-of-nomlabofusp-for-friedreichs-ataxia\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Larimar Therapeutics Completes Rolling BLA Submission Seeking Accelerated Approval of Nomlabofusp for Friedreich\u2019s Ataxia\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Larimar Therapeutics Completes Rolling BLA Submission Seeking Accelerated Approval of Nomlabofusp for Friedreich\u2019s Ataxia - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-completes-rolling-bla-submission-seeking-accelerated-approval-of-nomlabofusp-for-friedreichs-ataxia\/","og_locale":"en_US","og_type":"article","og_title":"Larimar Therapeutics Completes Rolling BLA Submission Seeking Accelerated Approval of Nomlabofusp for Friedreich\u2019s Ataxia - Market Newsdesk","og_description":"Completed BLA submission marks a major milestone in advancing nomlabofusp as the first potential disease-modifying therapy to address the underlying cause of FA Submission follows FDA alignment on key elements of the BLA package for submission, including willingness to consider skin frataxin as a potential novel surrogate endpoint Previously reported open label data showed sustained increases in skin frataxin with directional clinical improvements observed in multiple outcomes relative to a natural history reference population Patients currently enrolling in FORWARD-FA, the global confirmatory Phase 3 study for nomlabofusp BALA CYNWYD, Pa., Nov. 09, 2026 (GLOBE NEWSWIRE) &#8212; Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced completion of its rolling &hellip; Continue reading \"Larimar Therapeutics Completes Rolling BLA Submission Seeking Accelerated Approval of Nomlabofusp for Friedreich\u2019s Ataxia\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-completes-rolling-bla-submission-seeking-accelerated-approval-of-nomlabofusp-for-friedreichs-ataxia\/","og_site_name":"Market Newsdesk","article_published_time":"2026-11-09T22:43:00+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3Mjg3OCM3OTUyODg3IzUwMDA3Nzg4OQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"9 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-completes-rolling-bla-submission-seeking-accelerated-approval-of-nomlabofusp-for-friedreichs-ataxia\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-completes-rolling-bla-submission-seeking-accelerated-approval-of-nomlabofusp-for-friedreichs-ataxia\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Larimar Therapeutics Completes Rolling BLA Submission Seeking Accelerated Approval of Nomlabofusp for Friedreich\u2019s Ataxia","datePublished":"2026-11-09T22:43:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-completes-rolling-bla-submission-seeking-accelerated-approval-of-nomlabofusp-for-friedreichs-ataxia\/"},"wordCount":1737,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-completes-rolling-bla-submission-seeking-accelerated-approval-of-nomlabofusp-for-friedreichs-ataxia\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3Mjg3OCM3OTUyODg3IzUwMDA3Nzg4OQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-completes-rolling-bla-submission-seeking-accelerated-approval-of-nomlabofusp-for-friedreichs-ataxia\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-completes-rolling-bla-submission-seeking-accelerated-approval-of-nomlabofusp-for-friedreichs-ataxia\/","name":"Larimar Therapeutics Completes Rolling BLA Submission Seeking Accelerated Approval of Nomlabofusp for Friedreich\u2019s Ataxia - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-completes-rolling-bla-submission-seeking-accelerated-approval-of-nomlabofusp-for-friedreichs-ataxia\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-completes-rolling-bla-submission-seeking-accelerated-approval-of-nomlabofusp-for-friedreichs-ataxia\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3Mjg3OCM3OTUyODg3IzUwMDA3Nzg4OQ==","datePublished":"2026-11-09T22:43:00+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-completes-rolling-bla-submission-seeking-accelerated-approval-of-nomlabofusp-for-friedreichs-ataxia\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-completes-rolling-bla-submission-seeking-accelerated-approval-of-nomlabofusp-for-friedreichs-ataxia\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-completes-rolling-bla-submission-seeking-accelerated-approval-of-nomlabofusp-for-friedreichs-ataxia\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3Mjg3OCM3OTUyODg3IzUwMDA3Nzg4OQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3Mjg3OCM3OTUyODg3IzUwMDA3Nzg4OQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/larimar-therapeutics-completes-rolling-bla-submission-seeking-accelerated-approval-of-nomlabofusp-for-friedreichs-ataxia\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Larimar Therapeutics Completes Rolling BLA Submission Seeking Accelerated Approval of Nomlabofusp for Friedreich\u2019s Ataxia"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1019029","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1019029"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1019029\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1019029"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1019029"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1019029"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}